- Agriculture
- Antibiotic/anti-viral
- Biologics ×
- Biomarkers
-
By Clinical Application
- Anesthesiology
- Blood & Lymphatic Disease
- CNS & Neurosciences
- Dermatology
- Diabetes, Metabolism, Endocrinology & Obesity
- Ear, Nose, & Throat
- Emergency Services
- Gastroenterology & Digestive Disease
- General & Plastic Surgery
- Health Education, Medical Training and Operations
- Heart and Vascular
- Immunology, Autoimmune & Inflammation
- Infectious Diseases
- Mental Health
- Multiple clinical applications
- Musculoskeletal Disorders, Orthopedics/Bone
- Nephrology/Renal
- Oncology
- Ophthalmology
- Orphan Diseases
- Pediatrics
- Physical Medicine & Rehabilitation
- Radiology
- Regenerative Medicine / Tissue Engineering
- Reproductive Health: Obstetrics & Gynecology
- Respiratory & Pulmonary
- Surgery
- Transplantation
- Urology
- Wound Healing
- COVID-19
- Creative Works
- Diagnostics
- Drug Delivery
- Drug screening and discovery
- Energy, Cleantech & Environmental
- Engineering & Physical Sciences
- Gene therapy
- Imaging
- Materials
- Medical Devices
- Nutraceuticals
- Other
- Research & Design Tools
- RNAi/siRNA
- Sensors & Controls
- Small molecules
- Software & Information Technology
- Stem Cells
- Vaccines
- Veterinary Medicine
Showing 7 matches for the following: Inventor: "Chilkoti, Ashutosh" ×
Dual agonist proteins for the treatment of type 2 diabetes
Unmet Need Over 37 million people in the United States have diabetes, and approximately 90-95% of them have type 2 diabetes (T2D). Diabetes and its related complications not only cause premature mortality and lower quality…
Anti-cancer therapeutic for the induction of apoptosis in solid tumors via TRAIL receptors
Unmet Need Tumor necrosis factor-Related Apoptosis-Inducing Ligand (TRAIL, CD253) acts as an activator of apoptosis in many tumor cells, while remaining innocuous to normal cells. Both membrane-bound and soluble forms of TRAIL can trigger apoptosis…
Enzymatic synthesis of aptamer-targeted polynucleotide drug delivery platforms for cancer therapy
Unmet Need In the United States alone, over 1.8 million new patients were diagnosed with cancer in 2021, and over 600,000 patients died from the disease. Cytostatic nucleotides, such as gemcitabine and 5-fluorouracil, have been…
A class of biodegradable stealth polymers to improve drug delivery
Unmet Need Delivery of drugs or therapeutics such as small molecules, peptides, and proteins, in their native form, is limited by their poor stability, low solubility, and short in vivo circulation. These challenges in drug…
A method for treating TRAIL-resistant cancers
Unmet Need Over the past twenty years, TNF-related apoptosis-inducing ligand (TRAIL) has been shown to kill a variety of human cancer cells in vitro and in vivo while remaining innocuous to healthy cells. Unfortunately, the…
Increasing the half-life of therapeutic proteins and peptides using elastomeric-like polypeptides with environmental sensitivity
Value Proposition Since insulin was used as the first therapeutic protein in a clinical setting, the field of protein therapeutics has rapidly expanded. From 2014-2018, therapeutic proteins had the highest compound annual growth rate of…
Unstructured non-repetitive polypeptides as a tool for imparting temperature-dependent physical properties to protein fusions
Value Proposition Proteins can be useful therapeutic agents when engineered for specificity and selectivity for a clinical target. Their complexity, versatility, tolerability, and diversity often make them superior alternatives to small molecule drugs, and the…